.
Discussion
There is paucity of data on the safety of thrombolysis for AIS in cancer. We found no significant difference in primary outcomes or ICH between CSs and NCSs after thrombolysis, irrespective of type of thrombolysis or cancer subtype. A small single center study by Masrur et al, 8 which compared 44
CSs with 264 NCSs, also obtained similar results. However, outcomes based on cancer subtype were not studied. It is intriguing that solid tumors are associated with higher mortality given the lack of difference in ICH and comorbid conditions. This may be attributed to factors not available in the Nationwide Inpatient Sample database, such as admission stroke severity and cancer staging. Metastasis is the strongest predictor of mortality in patients with evidence of thrombosis 9 and accounts for the highest mortality in CSs. The higher prevalence of hypertension and hyperlipidemia in NCSs suggests that nonvascular risk factors are implicated in CSs.
Our study has a few limitations. First, our study included only patients with stroke treated with thrombolysis. The selection bias introduced with the inclusion of only CSs treated with thrombolysis precludes generalization of these results to a wider cancer population with stroke. The Nationwide Inpatient Sample database lacks information on admission stroke severity and stroke subtype. There is no information on modified Rankin Scale at 90 days. Coding error is also a possibility. There were no data on cancer staging and outpatient chemoradiation therapies, which may have influenced outcomes.
Conclusions
Our study suggests that thrombolysis for acute stroke is safe in patients with cancer. ICH rates are not higher in thrombolysistreated CSs. However, there is heterogeneity among cancer subtypes regarding response to thrombolysis. Prospective studies are warranted to validate these results.
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